Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
72.00    -1.00 (-1.37%)
Bid:
71.00
Ask:
73.00
Spread: 2.00 (2.817%)
Market Cap: £337.35m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Interim Results

26 Jan 2006 08:23

Readybuy PLC26 January 2006 Readybuy Plc Interim Announcement for the six months ended 31 October 2005 Chairman's Statement The results for the six months to 31 October show a loss of £85,000. Thisreflects the costs of closure of the manufacturing facility and also atermination payment to the former Chief Executive. The group has now exited completely from chilled food manufacturing. The ongoing costs are now minimal as the board seeks to preserve as much cash aspossible. We continue to explore a number of opportunities and I hope to be ableto announce some progress in the near future. Colin Davies Chairman READYBUY PLCGROUP PROFIT AND LOSS ACCOUNTfor the six months to 31 October 2005 Unaudited Audited Unaudited 6 months to Year to 6 months to 31/10/2005 30/04/2005 31/10/2004 Notes £'000 £'000 £'000 Turnover 4 313 139 ______ ______ ______ Operating loss (84) (252) (137) Provision for loss on operations to be discontinued - (804) - ______ ______ ______ Loss on ordinary activities before interest (84) (1,056) (137) Net interest (1) (2) (1) ______ ______ ______ Loss before taxation (85) (1,058) (138) Taxation - (45) - ______ ______ ______ Loss after taxation (85) (1,103) (138) Dividends - - - ______ ______ ______ Retained loss (85) (1,103) (138) ______ ______ ______ ---------- ----------- ---------- Loss per shareBasic and diluted 3 (0.4)p (6.1)p (0.8)p Dividends per share - - - The group's trading activities were terminated in July 2005, therefore all ofthe above activities are classified as discontinued. READYBUY PLCGROUP BALANCE SHEETat 31 October 2005 Unaudited Audited Unaudited 31/10/2005 30/04/2005 31/10/2004 £'000 £'000 £'000 Fixed assets Goodwill - - 629 Tangible assets - - 208 ______ ______ ______ - - 837 Current assetsStock - 2 17 Debtors 3 44 116Cash at bank 38 169 276 ______ ______ ______ 41 215 409 ______ ______ ______ Creditors falling due within one year (5) (194) (334) ______ ______ ______ Net current assets 36 21 75 ______ ______ ______ Total assets less current liabilities 36 21 912 Creditors falling due after one year - - (16) ______ ______ ______ 36 21 896 ______ ______ ______ ----------- ---------- ---------- Capital and reservesCalled up share capital 97 93 90Share premium account 1,425 1,329 1,242Profit and loss account (1,486) (1,401) (436) ______ ______ ______ Equity shareholders' funds 36 21 896 ______ ______ ______ ----------- ---------- ---------- READYBUY PLC GROUP CASHFLOW STATEMENT for the six months ended 31 October 2005 Unaudited Audited Unaudited 6 months to Year to 6 months to 31/10/2005 30/04/2005 31/10/2004 £'000 £'000 £'000 Operating loss (84) (252) (137) Gain on sale of fixed assets (25) - - Depreciation and amortisation - 67 33 Movement in working capital (21) 105 (17) Net cash outflow from operating activities (130) (80) (121) Net cash outflow from servicing of finance (1) (2) - Net cash inflow/(outflow) from capital expenditure and 25 (8) (6) financial investment Net cash outflow before use of liquid resources and financing (106) (90) (127) Capital element of finance lease payments (25) (34) (25) Repayment of convertible loans (100) - - Issue of ordinary share capital net of redemption 100 90 - Net cash (outflow)/inflow from financing (25) 56 (25) Decrease in cash in the period (131) (34) (152) Analysis of net funds Cash at bank and in hand 38 169 276 Overdraft - - (225) 38 169 51 Debt repayable by instalments: Due within one year - (25) (18) Due after more than one year - - (16) 38 (25) (34) 38 144 17 READYBUY PLCINTERIM ACCOUNTSfor the six months to 31 October 2005 Notes 1 The unaudited results for the six month period have been prepared on a basis consistent with the accounting policies disclosed in the Group's 2005 accounts and do not constitute statutory accounts within the meaning of Section 240 of the Companies Act 1985. 2 The figures for the period ended 30 April 2005 have been extracted from the statutory accounts which have been delivered to the Registrar of Companies and received an unqualified audit report. 3 The calculation of earnings per share for the period is based on the loss after taxation divided by the average number of ordinary shares in issue, being 19,240,387 (31 October 2004 - 17,994,010 and period ended 30 April 2005 - 18,066,870). This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
5th Sep 20187:15 amEQSHardman & Co Research: Avacta (AVCT): Capital increase for further development
5th Sep 20187:00 amRNSNotice of Results
31st Aug 20189:55 amRNSHolding(s) in Company
23rd Aug 20185:07 pmRNSHolding(s) in Company
23rd Aug 20185:06 pmRNSHolding(s) in Company
23rd Aug 201811:21 amRNSHolding(s) in Company
22nd Aug 20182:23 pmRNSHolding(s) in Company
22nd Aug 20189:20 amRNSHolding(s) in Company
17th Aug 201811:30 amRNSResult of General Meeting
6th Aug 20184:24 pmRNSHolding(s) in Company
30th Jul 20186:06 pmRNSResults of Placing and Subscription
30th Jul 201811:41 amRNSProposed Placing and Subscription to raise £11.4m
30th Jul 201810:35 amEQSHardman & Co Research: Avacta (AVCT): Ground-breaking new drug conjugate platform
24th Jul 20187:00 amRNSMajor Therapeutics Co-development Partnership
26th Jun 20181:30 pmEQSHardman & Co Research: Avacta (AVCT): Gearing up the management team
11th Jun 20187:00 amRNSAppointment of Non-Executive Chairman
31st May 201812:15 pmEQSHardman & Co Research: Avacta (AVCT): In vivo expression of Affimers
22nd May 20187:00 amRNSSuccessful Outcome of Study with FIT Biotech
30th Apr 20184:45 pmRNSHolding(s) in Company
17th Apr 20187:17 amEQSHardman & Co Research: Avacta (AVCT): Commendable rate of progress
16th Apr 20187:25 amRNSInterim Results
9th Apr 20182:58 pmRNSIssue of Equity
29th Mar 20187:00 amRNSAvacta to Present at Investor Forum
29th Mar 20187:00 amRNSDirectorate Change
13th Mar 201812:02 pmRNSDirector/PDMR Shareholding
7th Mar 20184:35 pmRNSPrice Monitoring Extension
8th Feb 20187:00 amRNSSummary of Capital Markets Day
22nd Jan 20187:00 amRNSAvacta and OncoSec to Collaborate
18th Jan 201811:26 amRNSResult of Annual General Meeting
18th Jan 20187:00 amRNSAGM Business Update and Notice of Results
15th Jan 201810:58 amRNSHardmanResearch: Affimer Drug Conjugates a reality
15th Jan 20187:00 amRNSDrug Development Partnership with Glythera
8th Jan 20187:00 amRNSCapital Markets Day Notification
4th Jan 201811:04 amRNSPDMR Dealing and Issue of Equity
3rd Jan 20187:00 amRNSPresenting at the Biotech Showcase, San Francisco
18th Dec 20174:28 pmRNSIssue of Equity
4th Dec 201711:03 amRNSPosting of Annual Report and Notice of AGM
30th Nov 201710:57 amRNSIssue of Equity
15th Nov 20177:00 amRNSCovance to Present Affimer Data at Conference
14th Nov 20173:27 pmRNSHolding(s) in Company
13th Nov 20177:00 amRNSAvacta to Present at Investor Evening
13th Nov 20177:00 amRNSAvacta to present at PEGS Europe
24th Oct 20177:00 amRNSAffimers in Scientific Publications
19th Oct 20177:00 amRNSPrivate Shareholder Update Event
16th Oct 201710:42 amRNSHardman Res.: R&D accelerated to advance assets
12th Oct 20177:00 amRNSAvacta to Present at Shares Spotlight Evening
10th Oct 20177:00 amRNSAvacta to Present at Major US Conference
9th Oct 20174:02 pmRNSDirector Dealing and Issue of Equity
5th Oct 20177:00 amRNSResearch collaboration with FIT Biotech Oy
4th Oct 20177:00 amRNSPreliminary Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.